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Abstract
Mannose-binding lectin (MBL) and the Mannose-binding lectin-associated serine proteases (MASPs) are an essential
aspect of innate immune responses that probably play an important but understudied role in cutaneous function.
The MBL-MASP pathway appears to exert its primary role by assisting in the clearance of apoptotic skin cells (thus
preventing accumulation and a subsequent autoimmune response) and promoting opsonophagocytosis of invad-
ing pathogens, limiting their dissemination. Deficiencies of the pathway have been described and are associated
with infectious, autoimmune and vascular complications. However, the role of this pathway in dermatological dis-
ease is essentially unexplored. We describe 6 patients presenting with recurrent inflammatory and/or infectious skin
conditions who also demonstrated severely low MBL levels. One patient also had a defect in the MASP2 gene.
Genotype analysis revealed specific point mutations in the MBL2 promoter in all 6 patients and a variant MASP-2
gene in one patient. Five patients presented recurrent pustular skin infections (cellulitis, folliculitis and cutaneous
abscess). A case of Grover’s disease and one forme fruste of Behcet’s syndrome (orogenital ulcers) were also
observed. The patients responded to antimicrobial therapy, although in some, recurrence of infection was the rule.
It appears that MBL deficiency may contribute to recurrent skin infections and to certain forms of inflammatory
skin disease. The mechanisms may relate to the role of this pathway in innate immunity, removal of apoptotic cells
and in immune complexes. Further study of MBL pathway defects in dermatological disease is required.
Introduction
The skin represents the largest organ of the innate
immune system, composing not only a physical barrier
but also containing numerous elements important in the
immunological response against invading pathogens (e.g.
keratinocytes, macrophages, Langerhans cells, dendritic
cells, dermal fibroblasts). Damage to this barrier predis-
poses the body to a more susceptible environment for
microbial dissemination, while improper immune sur-
veillance can be a triggering factor for several inflamma-
tory skin diseases [1]. This is an intricately orchestrated
defense system constituted by a local response at the
level of the epidermis and dermis, as well as by systemic
involvement, with migration of additional immune cells
to the site of antigenic stimulus.
A member of the collectin group of pattern recogni-
tion receptors, mannose-binding lectin (MBL) is part of
the innate immune system, a primordial defense
mechanism that serves as the initial response to host
invasion by pathogens in an antibody-independent fash-
ion (Figure 1). This is achieved through direct opsoniza-
tion of bacteria, recruitment of phagocytic cells that
promote phagocytosis of pathogens, along with comple-
ment activation and immunomodulatory cytokine pro-
duction that promote chemotaxis and recruitment of
inflammatory cells, thereby limiting pathogenic spread.
Defective MBL production is regarded as the most com-
mon immune deficiency in the general population,
affecting approximately 5-7% of individuals [2], although
some descriptions have delineated higher figures among
Caucasians (up to 30%) [3]. The implications of low
MBL levels have been the target of a large volume of
research, with an unequivocal influence on host
* Correspondence: krishnas@etsu.edu
2Internal Medicine, Quillen College of Medicine, East Tennessee State
University, Johnson City, TN 37614, USA
Miller et al. Clinical and Molecular Allergy 2010, 8:6
http://www.clinicalmolecularallergy.com/content/8/1/6 CMA
© 2010 Miller et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
susceptibility to a variety of recurrent infectious pro-
cesses and autoimmune disorders. However, propensity
to dermatological disease has not been explored to any
great extent. One report using MBL-deficient mice
demonstrated upregulation of inflammatory cytokines
and chemokines, thinning of the dermis and epidermis,
as well as eschar separation, in response to burn injury
[4]. Other investigators have suggested that diseases
such as atopic dermatitis, that present defects in innate
immunity, may have a defective MBL response [5].
Nevertheless, the role of MBL-MASP pathway defects in
dermatological disease is sparse, and we believe our
report to be the first to link MBL deficiency to recurrent
infectious and inflammatory skin disease in 6 patients.
Further studies in this area are obviously sorely
required. This is especially important as treatment with
recombinant MBL may soon be available and may assist
some patients with otherwise refractory or serious der-
matological disease.
Case Presentation
The study was approved by the Institutional Review
Board (East Tennessee State University) and the
Research and Development Committee of the James H.
Quillen Veterans Affairs Medical Center in Mountain
Home, Tennessee. The records of the patients were
reviewed and appropriate data collected. Immunoglobu-
lin assays were carried out in commercial laboratories
by traditional techniques. MBL genotyping and func-
tional assays were carried out by the IBT laboratories,
Lenexa, Kansas. MBL genotypes were assigned as per
Figure 2. Tables 1 and 2 list the laboratory results and
immunological evaluation in these patients.
Patient 1
A 39-year-old woman complained of recurrent pustular
eruption of her upper extremities and chronic allergic
rhinitis. Immunological evaluation demonstrated the
following: IgG levels were slightly decreased, but IgG
Figure 1 Schematic representation of the three complement activation pathways, converging to cleave C3. Classical pathway (activated
by immune complexes), MBL-pathway (activated by bacterial sugars such as mannose) and the alternate pathway (activated even in the
absence of antibody), result in formation of the C3 convertase, which culminates in C3 activation. After this occurs, C3b will opsonize the surface
of the pathogen, with subsequent phagocytosis. Further progression of the cascade leads to the activation of C5-9 and to the formation of the
membrane attack complex (MAC), lysing the microbe/cell. Byproducts of these pathways include anaphylotoxins C3a and C5a, recruiting
leukocytes which contribute to the inflammatory response.
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subclass levels were all normal. The patient had detect-
able/robust responses to 6/14 pneumococcal serotypes
(Table 1). Further work-up yielded a low level of MBL at
< 50 ng/ml (reference: >100 ng/ml), as well as an impaired
MBL pathway functional test using the C4b deposition
assay. Genotyping showed the HYPD/HYPD variant of
MBL2 and wild-type MASP-2 genotype (A/A) (Table 2).
Patient 2
A 61-year-old man presented with recurrent folliculitis-
like eruptions of the skin. His history was significant for
a prior history of infection of the cheek with methicil-
lin-resistant Staphylococcus aureus (MRSA) treated with
minocycline. Six years earlier, he had suffered infection
of a pacemaker site with MRSA, which had spread to
his upper extremities, but was ultimately controlled with
antibiotics. He denied intravenous drug use. Physical
examination revealed a 1-cm indurated nodule over his
left cheek, a 5 × 3 cm hyperpigmented patch over his
left ankle, and scattered areas of erythema over his ante-
rior chest wall and dorsum of his legs. MBL level was
< 50 ng/ml, while all classes of immunoglobulins were
within normal range (Table 1). MBL genotyping
revealed the LYPB/HYPD haplotypes. MASP-2 genotype
was the wild type (A/A). MBL functional pathway test
was impaired (Table 2). A skin biopsy of the folliculitis-
like rash (Figure 3, IV) was performed, revealing Gro-
ver’s disease (transient acantholytic dermatosis). Topical
therapy was instituted with triamcinolone.
Patient 3
A 47-year-old woman presented with a pustular rash
(Figure 3, I A, B and 3, I C) on her skin (face, back,
forearms and leg) and pustular inguinal eruptions; on
Figure 2 Molecular genetic and structural aspects of MBL. Representation of the gene organization of MBL2 (MBL1 is a pseudogene)and the
locations within Exon 1 that most commonly present polymorphisms, resulting in the variant alleles B, C, and D (codons 54, 57, and 52,
respectively), in addition to the P/Q variant at position +4 (5’-Unstranslated region). Upstream from Exon 1, the sites of promoter mutations that
lead to the H/L and X/Y variants are also demonstrated. The MBL2 gene is comprised of four exons. Exon 1 encodes the serine protease domain
(SP) (1), the cysteine-rich region (CRR) (2), and a portion of the collagen-like domain (CLD) (3); exon 2 encodes the remainder of the CLD; exon 3
encodes the neck region (4); and exon 4 encodes the carbohydrate-recognition domain (CRD) (5). Components of the MBL gene that process
transcription of these various components of the fully assembled MBL protein are also designated in this cartoon. Location of insert (A) showing
mutations on Exon map is represented by black arrow.
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one occasion she had developed a vulvar infection with
abscess formation requiring drainage. Past medical his-
tory included recurrent rhinosinusitis and anxiety disor-
der. Biopsy of the lesion showed pustular changes with
neutrophilic infiltration, but did not reveal lymphocyte
infiltration. A culture from a lesion on her forearm was
positive for Staphylococcus aureus. The patient
responded to administration of cefadroxil and minocy-
cline, with remission and frequent relapses. Laboratory
workup revealed mild C4 deficiency and an undetectable
IgE level (Table 1). Assays were unremarkable for ANA,
ESR, rheumatoid factor, hepatitis viruses, and HIV. The
MBL level was exceptionally low at < 50 ng/ml, and her
MBL functional pathway was impaired. MBL genotyping
revealed a LYPB/HYPD haplotype, while MASP-2 was
wild-type (Table 2).
Patient 4
49-year-old woman with complaints of a blistering skin
eruption and hyperpigmentation for the past 6 years; the
lesions were thick, tender, indurated, and presented with
yellow-green secretion. Her past medical history
included recurrent impetigo, perennial rhinitis, and
ulcerative colitis. On exam, a 1-inch area of induration
and erythema was observed over her chin (Figure 3II A
and 3II B); there were multiple scattered pustular lesions
over the forearms, some ulcerated. Encrusted pustules
were also observed over her scalp, face, back and legs.
Work-up yielded a weakly positive ANA and an elevated
CRP (10 mg/L) (Table 1). MBL levels were low at < 50
ng/ml. Punch biopsy from her forearm (Figure 3, II C)
revealed histopathology and morphology compatible
with Candida sphaerica, although the possibility of Tri-
chophyton rubrum was also raised; cultures were
attempted from a specimen but no growth was
observed. An aspirate of one of the pustules grew Sphin-
gomonas paucimobilis. Terbinafine and levofloxacin
were given, and her eruption resolved. Genotyping
revealed LXPA/LYPB for MBL and A/G for MASP-2
(Table 2). The MBL functional assay was also impaired.
Patient 5
A 48-year-old woman presented with painful orogenital
ulcerations. She had a family history of documented
Behcet’s disease (BD) in her father and brother and she
was concerned she may have the disease. She was
Table 1 Outline of additional immune deficiencies encountered in the patient group
Patient Laboratory assay Patient value Reference range





Functional MBL pathway (C3b deposition assay) 2.02 > 5.1
#2 Immunoglobulin and complement levels Normal
Functional MBL pathway (C3b deposition assay) 2.22 > 5.1
#3 C4 level Mild deficiency (1 null allele out of 4) 4 functioning alleles
Functional MBL pathway (C3b deposition assay) 2.04 > 5.1
#4 Immunoglobulin and complement levels Normal
C-reactive protein 10 mg/L < 6 mg/L
Antinuclear antibody 1/8 (weakly positive) < 1/8
Functional MBL pathway (C3b deposition assay) 2.10 > 5.1
#5 Immunoglobulin and complement levels Normal
Functional MBL pathway (C3b deposition assay) 2.18 > 5.1
#6 IgG3 34 mg/dL 41-129 mg/dL
Functional MBL pathway (C3b deposition assay) Not available
Table 2 Summary of clinical scenarios and respective genotyping results
Patient Clinical condition MBL2 MASP-2
#1 Rhinoconjunctivitis and recurrent upper extremity skin infections HYPD/HYPD A/A
#2 History of MRSA pacemaker infection and recurrent folliculitis LYPB/HYPD A/A
#3 Recurrent S. aureus folliculitis LYPB/HYPD A/A
#4 Fungal folliculitis LXPA/LYPB A/G
#5 Forme fruste of Behçet’s disease LXPA/LYPB A/A
#6 Recurrent lower extremity cellulitis and ulcerations LYPB/LYPB A/A
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uncertain as to whether she was of Melungeon descent
(peoples of Tri-racial descent who have lived in the
South-Eastern United States: these include European,
African/Middle Eastern/Turkish and Native American).
Pertinent other history included severe polyarthralgia
(hands, wrists, arms, knees, and ankles) over the past 8
years.
A pathergy test was negative. Immunoglobulin levels,
ESR, and CRP were unremarkable. Assays for hepatitis
viruses, HIV, rheumatoid factor, Herpes simplex, and
lupus anticoagulant were negative (Table 1). Ophthal-
mologic evaluation did not demonstrate the characteris-
tic uveitis. She was treated with a pulse of oral
glucocorticoids and placed on long term hydroxychloro-
quin. After 5 months, oral and genital ulcerations had
resolved. Due to the clinical response to therapy but
insufficient diagnostic criteria, she was diagnosed with a
forme fruste of BD. Further work-up established an
MBL level < 50 ng/ml and a deficient MBL functional
pathway (Table 1). Genotyping revealed an LXPA/LYPB
haplotype for MBL and A/A for MASP-2 (Table 2).
Patient 6
A 56-year-old Caucasian man complained of recurrent
bilateral lower extremity cellulitis and ulcerations,
requiring hospitalization and parenteral antibiotic
administration. History included factor V Leiden muta-
tion with recurrent lower extremity deep venous throm-
boses and recurrent MRSA urinary tract infections. He
had undergone numerous abdominal procedures, with
recurrent enterocutaneous fistulae and wall abscesses.
Abdominal exam revealed wall ulceration with serosan-
guineous drainage and surrounding erythema. His lower
extremities presented ochre dermatitis, bilateral +/4
Figure 3 Patients with MBL deficiency and dermatological disease. Figures I A, B and C demonstrates pustular skin eruption, with biopsy
showing neutrophilic inflammation in patient #3. Figures II A, B and C demonstrate fungal folliculitis with PAS stain (C), demonstrating fungal
hyphal elements in patient #4. Figure III shows lower extremity cellulitis and inflammatory ulcer of patient #6, and figure IV demonstrates
folliculitis-like rash of patient #2 with Grover’s Disease and history of recurrent staphylococcal skin infections.
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edema below the knee; there were 2 ulcerations on the
anterior portion of his left leg, measuring 1 × 1 cm and
2 × 3 cm (Figure 3, III). A lower extremity ultrasound
showed a left-sided nonocclusive chronic thrombus in
the femoral and popliteal veins. Total levels of immuno-
globulins were normal (except for a small decrease in
IgG3), as were C2 and C4 (Table 1). Anticardiolipin
antibody was negative. The patient had a low level of
MBL (<50 ng/ml), genotyping showing a LYPB/LYPB
polymorphism for MBL and a wild-type MASP-2 (Table
2). The patient’s abdominal wall culture grew cephalos-
porin-sensitive Staphylococcus aureus; cultures from his
lower extremity ulcerations were positive for Pseudomo-
nas aeruginosa. The patient responded to antimicrobials,
compression stockings and topical Tacrolimus©.
Disscussion
The MBL-MASP pathway of complement activation
results in multiple beneficial effects in the innate
response to pathogens. Deficiencies of the MBL-MASP
pathway have been linked to recurrent and serious
infections, atopic disease, and autoimmunity, as well as
to cardiovascular pathology. However, the role of this
pathway in dermatological disease has not been studied
adequately.
The circulating MBL-2 protein is an oligomeric mole-
cule formed by three identical polypeptides which spiral
around each other in a tight helix to form a subunit,
several of which link together to compose higher-order
oligomers (Figure 2). It is through the carbohydrate-
recognition domain (CRD) that pathogen-associated
molecular patterns (PAMPs) are recognized and bound,
with biological activity occurring through clustering of
CRDs and multiple carbohydrate binding to the widely-
spaced, repetitive sugars on the surface of pathogens
[6-8]. Upon binding to PAMPs, the MBL pathway and
MASP recruitment are activated. MASP-2 is analogous
to C1s as it forms C3 convertase by sequentially cleaving
C4 and C2. Deposition of C3b on the microbial cell sur-
face is the common point between the 3 complement
pathways, after which either opsonophagocytosis will
occur or the membrane attack complex will form pores
in the cell wall and lead to osmotic lysis (Figure 1).
There are three functional single nucleotide poly-
morphisms within exon 1 of the MBL2 gene which lead
to low serum MBL levels. The A allele is also termed
“wild-type” and is usually associated with normal MBL
levels. The variant alleles (B, C and D) are collectively
termed O alleles and confer a distorted molecular struc-
ture, as well as low serum MBL. There are seven MBL2
haplotypes, 4 of which are associated with decreased
MBL levels (LYPB, LYQC, HYPD, and LXPA), the other
3 (HYPA, LYPA, and LYQA) producing normal levels
[9]. Serum MBL will be about one-fifth of normal range
in heterozygotes and less than 2% in homozygotes or
compound heterozygotes [10].
Alternative splicing and polyadenylation of the MASP-
2/MAp19 gene lead to encoding of MASP-2 and
MAp19. Recent reports have identified a mutation in
exon 3 of this gene leading to the exchange of aspartate
with glycine at position 105 (D105G) within the CUB1
domain, causing impaired binding to MBL, and also low
circulating plasma levels of MASP-2 [11,12]. Wild-type
genotypes (AA) present with normal serum levels of
MASP-2, while homozygotes for the mutation (GG) will
display little or no lectin pathway activity. Heterozygous
genotypes (AG) confer approximately half the amount
of circulating MASP-2.
The patient in Case 1 manifested recurrent upper
respiratory tract infections, most likely of an occupa-
tional nature, in addition to repeated skin findings. The
exact nature of her skin condition was not clearly eluci-
dated, but the fact that she presented a good response
to antihistamine and steroid therapy suggests atopy,
reinforced by concomitant respiratory tract involvement.
The association between recurrent upper respiratory
infections and MBL deficiency has been grounds for
debate by a number of studies [13-16]. MBL promotes
complement-mediated killing of a number of upper
respiratory pathogens [17,18]. In the case of pneumo-
coccus, MBL has an ancillary part in promoting opsono-
phagocytosis, and low serum levels have been associated
with increased mortality [19]. Our patient displayed
mild deficiency in total IgG with normal subclasses,
manifest through a diminished antipneumococcal immu-
noglobulin production, which may occur in the absence
of a specific subclass deficiency [20].
In Case 2, the development of MRSA infection at the
site of pacemaker placement may have been a trigger
for recurrent skin findings, with several failed attempts
at eradicating the organism. MBL participates in first-
line defense against S. aureus via opsonophagocytosis by
macrophages and neutrophils [21]. The MBL-MASP
complex has a significant role in increasing C3b deposi-
tion on the surface of S. aureus [22], contributing to an
increase in its engulfment by neutrophils. In addition,
C3b combines with factor B to generate the alternative
pathway convertase (C3bBb), which promotes further
breakdown of C3b [23]. Thus, the lectin and alternative
pathways have developed mutual amplification loops
[24], although experimental evidence suggests that the
alternative pathway has a much greater influence on
controlling staphylococcal bacteremia than the lectin or
classical pathway [25]. In addition, MBL triggers macro-
phage release of cytokines in response to bacterial inva-
sion, enhancing neutrophilic activity. MBL is a
modulator of inflammation, interacting with toll-like
receptors in NF-B-dependent production of TNF-a;
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the latter is a crucial element in host defense, and its
deficiency impairs recruitment of neutrophils and pha-
gocytosis [26]. MBL-null mice incubated with intrave-
nous S. aureus had a blunted production of TNF-a and
interleukin-6 (IL-6) reversible by pretreatment with
recombinant human MBL (rhMBL) [21]. The influence
of the C4 deficiency in our third patient is questionable,
highlighted by a murine study by Cunnion et al. show-
ing similar mortality from bacteremia caused by encap-
sulated S. aureus as compared to controls with normal
C4 [25].
A potentially confounding factor in Case 2 is the con-
current diagnosis of Grover’s disease, which has been
associated with immunodeficiency [27]. Although
usually self-limited, one-third of patients may be refrac-
tory to therapy. Of note, success in treating this condi-
tion with antibiotics or antimycotics should raise
questions about the veracity of the diagnosis [27].
The role of MBL deficiency in recurrent fungal follicu-
litis is not entirely clear, but it is likely that fungal man-
nan may be able to activate the complement cascade
that then leads to activation of a phagocytic and cellular
immune response. Defense against dermatophyte infec-
tion relies greatly on cell-mediated immunity to destroy
the stratum corneum in which the pathogens reside
(seen as how complement and humoral elements have
limited access to this layer), aided by a Th1-type delayed
hypersensitivity reaction [28-31]. MBL has been shown
to have a strong binding affinity for Candida albicans
and acts in first-line defense against this organism,
increasing C3 deposition on its surface and hence pha-
gocytosis by neutrophils [32,33].
Due to the diagnosis of BD in 2 other family members,
a possible familial clustering was suggested in Case 5, as
this disease has a strong genetic influence and is distribu-
ted within certain geographic locations (i.e. Mediterra-
nean and Asia) [34,35]. Unfortunately, an accurate
familial background was not provided by the patient. A
potential role for microorganisms (e.g. streptococci,
viruses) has been suggested in the etiopathogenesis of
BD, due to a hyperactive response to bacterial antigens
and/or heat shock proteins in an already proinflamma-
tory state [36,37]. Hence, innate immunity would be
essential in limiting invasion and an exaggerated immune
response, with MBL deficiency representing a susceptibil-
ity and severity factor in BD [37]. Apart from impairing
local defenses (potentially facilitating recurrent oral
ulcers), low MBL levels allows a more constant patho-
genic stimulation, leading to immune cell infiltration and
a Th1-type cytokine profile (with increased levels of IL-
12 and interferon-g) [36,37]. In addition, MBL has an
important role in clearance of apoptotic cells (MBL is
recruited from noncutaneous sources to bind apoptotic
keratinocytes and induce their uptake by dendritic cells)
[38], the accumulation of which can favor autoimmunity,
as the release of intracellular components triggers inflam-
matory cytokine production and development of reactive
clones, leading to autoantibody formation [39,40]. In the
specific case of BD, there are large numbers of PMNs
located within mucocutaneous lesions, and MBL defi-
ciency contributes to impaired clearance of these cells
after they undergo apoptosis, precipitating the immune
response described [37]. Of note, the negative pathergy
test (intradermal saline injection looking for a granulo-
matous reaction at the injection site) displayed by our
patient does not exclude the diagnosis, as it is only posi-
tive in around 30% of cases.
In addition to recurrent infections with S. aureus and
P. aeruginosa, against which MBL plays a role in primary
defense, the patient in Case 6 presented with compli-
cated postoperative courses. Postoperative infections
have already been shown to occur at a greater rate in
MBL-deficient patients (haplotype A/O, O/O in exon 1
and AX/AX), and preoperative serum levels are actually a
form of identifying patients at risk [41,42]. Now, while
MBL deficiency has been shown to predispose to arterial
thrombosis in patients with autoimmune disorders, no
increased risk for development of venous thrombosis was
demonstrated [43]. But, in this particular case, his hyper-
coagulable condition is the most likely culprit.
The major limitation in our study is the small number
of cases, the lack of appropriate controls and the high
frequency of MBL deficiency in the population. This
might suggest that these findings are coincidental and
that MBL deficiency may have no relationship to the
infections experienced by the reported group of patients.
Nevertheless, we feel this report is among the first to
connect recurrent and sometimes serious skin infections
and inflammatory conditions to the MBL-MASP path-
way. We hope this report will lead others to look for
these defects. Finally, this series of case reports could
lead to a better-designed study to evaluate the preva-
lence and significance of MBL-MASP pathway defects in
patients with cutaneous infections. Also of note, it is
likely that in a subset of patients, MBL deficiency may
need to be accompanied by yet another immune defect,
such as in the classical complement, humoral immune
or phagocytic pathways to manifest infection (such as
has been demonstrated in patients with chemotherapy-
related infection). The pathogenic role of MBL-MASP
pathway in infectious and inflammatory dermatoses
needs to be defined and more studies are required.
A number of our patients would be likely candidates
for MBL replacement therapy, particularly those who
did not display a satisfactory response to conventional
therapies. Several trials have met with promising results
in Europe, but use of recombinant human MBL
(rhMBL) in the United States is not yet approved.
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Recently, a second-generation plasma-derived MBL
(pMBL) product has been manufactured and is under-
going phase II trials. Work with stem cell preparations
has given ground to new hypotheses suggesting possible
cell-signaling properties inherent to MBL replacement
therapy, which may include induction of immunologic
maturation in autologous cells, in addition to simply
increasing the serum levels for the extent of half-life of
the product [44].
Conclusions
The MBL-MASP pathway of complement activation is
of importance to innate immunity and to response to
pathogens. While defects in the pathway have been
linked to infectious, vascular and autoimmune disease,
no prior reports have stressed the importance of these
defects to dermatological disease. We present six cases
who had profound defects in the MBL-MASP pathway
and who developed serious cutaneous infectious and/or
inflammatory disease. It appears that MBL deficiency
may contribute to recurrent skin infections and to cer-
tain forms of inflammatory skin disease. The mechan-
isms may relate to the role of this pathway in innate
immunity, removal of apoptotic cells and immune com-
plexes. Further study of MBL pathway defects in derma-
tological disease is required as it may open up treatment
options with recombinant MBL protein (when available)
for patients with difficult-to-treat dermatological
infections.
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